Close
FINDING CURES TOGETHER<sup>SM</sup>

Translational Control of Cancer: A New Frontier in Cancer Biology and Therapy

​October 27-30, 2016
Hyatt Regency San Francisco
San Francisco, California

Conference Co-chairpersons
Jennifer A. Doudna, University of California, Berkeley, Berkeley, California
Frank McCormick, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California
Davide Ruggero, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California
Nahum Sonenberg
, McGill University, Montreal, Quebec, Canada

There have been dramatic advances in our understanding of the post-transcriptional circuitry which drives the expression of the cancer genome. In particular, alterations in translational control underlie key steps in cancer progression and represent major drivers of the fitness, evolution, and development of a transformed cellular phenotype. 

All major oncogenic pathways, including PI3K-AKT-mTOR, RAS, as well as oncogenes like Myc, directly control the expression and activity of many components of the translation machinery, such as rDNA, ribosomal proteins, translation initiation, and elongation factors. New studies have uncovered that these pathways induce transcript-specific changes in translation, affecting cancer cell fate and therapeutic response. Additional research efforts are centered on understanding the cis-regulatory elements that modulate the expression of key mRNAs translationally deregulated in cancer. Importantly, just as the field of translation control in cancer is advancing at a fast rate, new compounds that directly block aberrant protein synthesis in cancer are also being developed and tested in the clinic.

This AACR Special Conference will provide an exciting forum to discuss the emerging advances in understanding translation regulation and cancer development, including: reprogramming of the cancer genome downstream oncogenic signaling, new regulatory elements embedded in the mRNAs of the translation cancer program, the different codon usage in normal and transformed cells, ribosome composition in cancer cells, innovating high-throughput technologies to decode the translational landscape of cancer cells, and how translation control steers adaptive responses to oncogenic stress. We will also discuss new therapeutic interventions and drug discoveries for targeting aberrant translation control in cancer.

Special Conference Series Supporter:

Bristol-Myers Squibb


Supporters:

​Amgen​AstraZeneca
Merck


#AACRTCC16